BioTuesdays

ASLAN Pharma gears up for data rich second half

By Len Zehrs ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the...

Australia tax incentives spurring R&D

By Len Zehrs Australia is riding a wave of R&D, thanks to generous government tax incentives, as well as the quality of contract research and speed of performing clinical trials. The incentives provide businesses...